Literature DB >> 25992284

Severe reversible pulmonary hypertension in smoldering multiple myeloma: two cases and review of the literature.

Wayne L Feyereisn1, Eric R Fenstad2, Robert B McCully2, Martha Q Lacy3.   

Abstract

An association between pulmonary hypertension (PH) and POEMS syndrome (characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) as well as other plasma cell dyscrasias, including multiple myeloma (MM), has been shown to exist. Recent case reports have identified a reversible form of PH that occurs outside of previously identified etiologies. We report two cases of PH in the setting of smoldering MM (SMM) that resolved with chemotherapy and stem cell transplantation. Although other features were individualized among the cases (dermatomyositis, scleromyxedema), treatment of MM and SMM resulted in a normalization of right ventricular systolic pressure and improvement in right ventricular dysfunction that was previously unresponsive to PH therapies. The magnitude and sustained nature of reversibility in these four cases could offer clues about the pathophysiology and treatment of PH.

Entities:  

Keywords:  hypertension pulmonary; multiple myeloma; outcomes

Year:  2015        PMID: 25992284      PMCID: PMC4405708          DOI: 10.1086/679726

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  15 in total

1.  Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma.

Authors:  E Antonioli; C Nozzoli; G Gianfaldoni; F Mannelli; S Rossi; S Betti; P Bernardeschi; G Fiorentini; A Bosi
Journal:  Ann Oncol       Date:  2005-07-12       Impact factor: 32.976

Review 2.  Updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

3.  Growth factors in POEMS syndrome: evidence for a marked increase in circulating vascular endothelial growth factor.

Authors:  M Soubrier; J J Dubost; A F Serre; J M Ristori; B Sauvezie; P Cathebras; J C Piette; A Chapman; F J Authier; R K Gherardi
Journal:  Arthritis Rheum       Date:  1997-04

4.  Pulmonary hypertension in patients with amyloidosis.

Authors:  D Dingli; J P Utz; M A Gertz
Journal:  Chest       Date:  2001-11       Impact factor: 9.410

5.  Unexplained pulmonary hypertension in chronic myeloproliferative disorders.

Authors:  D Dingli; J P Utz; M J Krowka; A L Oberg; A Tefferi
Journal:  Chest       Date:  2001-09       Impact factor: 9.410

6.  Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

Authors:  María-Victoria Mateos; Miguel-Teodoro Hernández; Pilar Giraldo; Javier de la Rubia; Felipe de Arriba; Lucía López Corral; Laura Rosiñol; Bruno Paiva; Luis Palomera; Joan Bargay; Albert Oriol; Felipe Prosper; Javier López; Eduardo Olavarría; Nuria Quintana; José-Luis García; Joan Bladé; Juan-José Lahuerta; Jesús-F San Miguel
Journal:  N Engl J Med       Date:  2013-08-01       Impact factor: 91.245

7.  Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines.

Authors:  P Lesprit; B Godeau; F J Authier; M Soubrier; M Zuber; C Larroche; J P Viard; B Wechsler; R Gherardi
Journal:  Am J Respir Crit Care Med       Date:  1998-03       Impact factor: 21.405

8.  Expression of vascular endothelial growth factor and its receptors correlates closely with formation of the plexiform lesion in human pulmonary hypertension.

Authors:  S Hirose; Y Hosoda; S Furuya; T Otsuki; E Ikeda
Journal:  Pathol Int       Date:  2000-06       Impact factor: 2.534

9.  Pulmonary manifestations in patients with POEMS syndrome: a retrospective review of 137 patients.

Authors:  Joanne Shirine Allam; Cassie C Kennedy; Timothy R Aksamit; Angela Dispenzieri
Journal:  Chest       Date:  2008-01-15       Impact factor: 9.410

10.  Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.

Authors:  Robert A Kyle; Ellen D Remstein; Terry M Therneau; Angela Dispenzieri; Paul J Kurtin; Janice M Hodnefield; Dirk R Larson; Matthew F Plevak; Diane F Jelinek; Rafael Fonseca; Lee Joseph Melton; S Vincent Rajkumar
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

View more
  2 in total

1.  Pulmonary Vascular Disease Due to Plasma Cell Dyscrasia.

Authors:  Indranee Rajapreyar; Joanna Joly; Jose Tallaj; Salpy V Pamboukian; Ayman Haj Assad; Carrie Lenneman; Silvio Litovsky; Arka Chatterjee; Charles Hoopes; Andrew Lenneman
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2020-11-20

2.  Clinical impact of echocardiography-defined pulmonary hypertension on the clinical outcome in patients with multiple myeloma.

Authors:  SungA Bae; Kye Hun Kim; Hyun Ju Yoon; Hyung Yoon Kim; Hyukjin Park; Jae Yeong Cho; Min Chul Kim; Yongcheol Kim; Young Joon Hong; Hyung Wook Park; Ju Han Kim; Youngkeun Ahn; Myung Ho Jeong; Jeong Gwan Cho; Jong Chun Park
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.